ArticleCureus2024
Hemophagocytic Lymphohistiocytosis Secondary to Miliary Tuberculosis in a Resource-Limited Setting: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2026Article
- Hemophagocytic Lymphohistiocytosis Secondary to Extrapulmonary Tuberculosis in an HIV Patient: A Case Report.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis is a rare life-threatening condition, with a high mortality rate, characterized by a dysfunctional immune response resulting in multi-organ damage. The secondary or sporadic form of the disease can be triggered by a multitude of infections, malignancies, and autoimmune disorders. Tuberculosis is commonly involved as a trigger for hemophagocytic lymphohistiocytosis. In a rare case, a 52-year-old gentleman with advanced human immunodeficiency virus (HIV) and disseminated tuberculosis (TB) developed secondary hemophagocytic lymphohistiocytosis. This patient was successfully treated with the 1994 hemophagocytic lymphohistiocytosis treatment protocol at a hospital in a rural province in South Africa. TB, a treatable condition, remains the most lethal disease in South Africa. This case highlights another severe complication of TB. Despite the widespread rollout of antiretroviral treatment, HIV still remains South Africa's largest epidemic. This case emphasizes the need for physicians, treating people living with HIV infection and TB, to have a high index of suspicion in the appropriate clinical situation for hemophagocytic lymphohistiocytosis. Improved outcomes are possible for these cases when diagnosed and treated timely and correctly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.